Carisma Therapeutics, Inc.
CARM
$0.2351
$0.00934.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -48.01% | 32.45% | 31.59% | 41.13% | 57.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -48.01% | 32.45% | 31.59% | 41.13% | 57.95% |
| Cost of Revenue | -46.35% | -31.46% | -19.50% | -12.75% | 4.27% |
| Gross Profit | 45.68% | 47.55% | 32.37% | 25.99% | 8.37% |
| SG&A Expenses | -34.29% | -26.76% | -31.79% | 1.55% | 22.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.24% | -30.27% | -23.00% | -9.30% | 8.48% |
| Operating Income | 41.94% | 41.36% | 32.18% | 18.17% | 0.05% |
| Income Before Tax | 32.08% | 37.58% | 30.39% | 22.39% | 8.43% |
| Income Tax Expenses | -- | -- | -- | -200.00% | -200.00% |
| Earnings from Continuing Operations | 31.89% | 37.49% | 30.39% | 22.82% | 8.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.89% | 37.49% | 30.39% | 22.82% | 8.90% |
| EBIT | 41.94% | 41.36% | 32.18% | 18.17% | 0.05% |
| EBITDA | 42.10% | 41.46% | 33.84% | 19.57% | 0.75% |
| EPS Basic | 33.60% | 39.31% | 57.94% | 85.26% | 90.31% |
| Normalized Basic EPS | 42.44% | 41.78% | 59.25% | 85.20% | 90.28% |
| EPS Diluted | 33.60% | 39.31% | 57.94% | 85.26% | 90.31% |
| Normalized Diluted EPS | 42.44% | 41.78% | 59.25% | 85.20% | 90.28% |
| Average Basic Shares Outstanding | 2.29% | 2.95% | 24.01% | 72.16% | 184.10% |
| Average Diluted Shares Outstanding | 2.29% | 2.95% | 24.01% | 72.16% | 184.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |